INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.155
-0.015 (-0.69%)
Aug 17, 2026, 1:57 PM EDT - Market open

INmune Bio Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-0.050.010.160.370.18
Revenue Growth
-257.14%-90.97%-58.56%106.63%1545.45%
Gross Profit
-0.050.010.160.370.18
Operating Income
-20.2-30.87-42.64-29.74-25.95-29.15
Net Income
-18.42-45.93-42.08-30.01-27.3-30.34
Earnings Per Share
-0.69-1.86-2.11-1.67-1.52-1.88
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
18.4124.7520.9235.8552.1574.81
Total Debt
1.411.030.3810.4415.3115.23
Net Cash (Debt)
17.0123.7220.5425.4136.8459.58
Net Cash Growth
-48.35%15.48%-19.18%-31.03%-38.16%173.20%
Net Cash Per Share
0.640.961.031.412.063.69

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-14.96-22.58-33.36-11.98-22.69-28.5
Capital Expenditures
-0.77-1.04----
Free Cash Flow
-15.73-23.62-33.36-11.98-22.69-28.5
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-100.00%100.00%100.00%100.00%100.00%
Operating Margin
--61738.00%-304535.71%-19187.74%-6938.77%-16106.63%
Pretax Margin
--91866.00%-300585.71%-19360.00%-7299.20%-16762.43%
Profit Margin
--91866.00%-300585.71%-19360.00%-7299.20%-16762.43%
FCF Margin
--47248.00%-238292.86%-7729.03%-6065.77%-15748.07%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
-829.467396.101309.19304.221005.53